Key facts
- It has raised $20K; the latest was Seed Round ($20K) in Dec 2024.
- Notable investors include KPTL, Supera Incubator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Eleve Science
- ·The full record, as it builds
Funding rounds
No funding rounds for Eleve Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eleve Science
Developer of a technology-driven platform designed to advance in vitro safety and efficacy assessment. The company offers specialized expertise in predictive modeling and drug delivery systems, and research and development, enabling clients to improve product safety and efficacy testing while minimizing the need for traditional in vivo models.
- Sector
- Healthcare
- HQ
- Sao Paulo, Brazil
- Employees
- 18
- Website
- elevescience.com.br/
- Ownership
- Privately Held (backing)
Eleve Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eleve Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eleve Science in its N-PORT filings yet. We sweep new filings monthly.